kawasaki
diseas
kd
acut
febril
childhood
vascul
associ
develop
coronari
arteri
abnorm
untreat
patient
aetiopathogenesi
well
known
accept
undefin
infecti
trigger
genet
predispos
individu
result
diseas
kd
character
endotheli
cell
injuri
could
due
abnorm
cytokin
product
gener
cytotox
antibodi
endotheli
cell
intraven
immunoglobulin
ivig
effect
treatment
prevent
occurr
coronari
arteri
abnorm
kd
sever
mechan
may
explain
antiinflammatori
effect
ivig
diseas
includ
modif
cytokin
balanc
alter
differenti
function
monocytesmacrophag
neutrophil
lymphocyt
kawasaki
diseas
kd
acut
childhood
vascul
first
describ
tomasaku
kawasaki
kd
character
high
fever
rash
cervic
lymphadenopathi
conjunct
oral
enanthema
erythemat
indur
hand
feet
symptom
resolv
spontan
within
week
soon
earli
treatment
intraven
immunoglobulin
ivig
aspirin
inflamm
mediums
arteri
throughout
bodi
particularli
coronari
arteri
occur
acut
ill
result
coronari
arteri
aneurysm
untreat
patient
kd
common
acquir
heart
diseas
children
develop
countri
although
treatment
ivig
effect
therapi
kd
children
respond
mechan
action
remain
fulli
establish
identif
etiolog
kd
would
greatli
enhanc
effort
develop
diagnost
test
improv
therapi
prevent
kd
recent
year
wit
emerg
interest
find
etiopathogenesi
therapi
kd
review
focu
immunolog
aspect
kd
aetiopathogenesi
immunomodulatori
effect
ivig
kd
common
vascul
infanc
major
complic
acut
febril
vascul
long
term
cardiac
consequ
diagnost
test
avail
kd
diagnost
criteria
establish
japanes
ministri
health
research
committe
adopt
american
heart
associ
american
academi
pediatr
tabl
patient
fever
least
day
present
less
princip
criteria
diagnos
kd
coronari
arteri
abnorm
detect
echocardiographi
angiographi
presenc
princip
criteria
diagnosi
kd
made
day
ill
coronari
arteri
aneurysm
may
progress
subacut
phase
sever
case
kd
lead
heart
attack
coronari
arteryaneurysm
ruptur
andor
sudden
death
children
kd
febril
less
main
featur
may
still
develop
coronari
arteri
dilat
aneurysm
classifi
incomplet
kd
particularli
challeng
diagnosi
common
infant
month
serial
echocardiographi
perform
center
experienc
examin
coronari
arteri
children
need
patient
acut
kd
children
uncompl
cours
echocardiographi
repeat
two
week
six
eight
week
diagnosi
laboratori
find
specif
kd
share
acut
inflammatori
febril
diseas
leukocytosi
neutrophil
immatur
cell
elev
erythrocyt
sediment
rate
esr
elev
creactiv
protein
crp
anemia
abnorm
plasma
lipid
hypoalbuminemia
hyponatremia
thrombocytosi
week
steril
pyuria
elev
serum
transaminas
elev
serum
gamma
glutamyl
transpeptidas
pleocytosi
cerebrospin
fluid
leukocytosi
synovi
fluid
predict
factor
aneurysm
identifi
male
sex
age
month
year
creactiv
protein
mgdl
albumin
gl
platelet
count
l
delay
initi
ivig
lower
dose
ivig
recurr
kd
caus
kd
remain
unknown
gener
accept
undefin
infecti
trigger
genet
predispos
individu
result
diseas
genet
predisposit
suspect
base
clinic
epidemiolog
featur
although
kd
report
world
diseas
overexpress
among
asian
popul
especi
japanes
japanes
incid
year
age
time
greater
among
caucasian
year
age
light
absenc
associ
kd
specif
hla
type
shulman
et
al
investig
relationship
distribut
immunoglobulin
allotyp
marker
suscept
kd
japanes
japaneseamerican
white
american
popul
immunoglobulin
allotyp
repres
anoth
system
human
genet
marker
found
popul
studi
differ
observ
patient
kd
racematch
control
subject
white
patient
kd
allotyp
marker
close
resembl
japanes
popul
substanti
higher
incid
kd
polymorph
sever
immun
gene
chemokin
receptor
chemokin
cc
motif
ligand
inositol
phosphat
kinas
c
implic
compat
etiolog
probabl
infecti
clinic
featur
kd
support
infecti
caus
includ
abrupt
onset
symptom
resolut
ill
week
even
without
treatment
usual
without
recurr
young
age
group
affect
case
present
first
second
year
life
suscept
ubiquit
agent
highest
winterspr
predomin
case
nontrop
climat
exist
epidem
cluster
case
mani
possibl
aetiolog
featur
agent
suggest
includ
mercuri
rickettsialik
agent
propriobacterium
acn
rug
shampoo
leptospira
spp
streptococcu
sangui
retroviru
tabl
clinic
featur
kawasaki
diseas
fever
least
five
day
durat
polymorph
exanthema
bilater
nonexud
conjunctiv
inject
chang
oral
caviti
includ
strawberri
tongu
erythemat
fissur
lip
inject
pharynx
chang
peripher
extrem
includ
erythema
indur
oedema
later
desquam
cervic
lymphadenopathi
often
unilater
larg
cm
epsteinbarr
viru
cytomegaloviru
toxic
shock
syndrom
toxin
bacteri
toxin
coronaviru
human
bocaviru
previous
unrecogn
persist
rna
viru
howev
none
aetiolog
featur
confirm
subsequ
studi
hypothesi
bacteri
toxin
caus
kd
favor
investig
theori
base
clinic
similar
kd
staphylococc
streptococc
toxinmedi
ill
peel
hand
feet
strawberri
tongu
addit
acut
kd
mani
cytokin
regul
serum
patient
overrepresent
particular
tlymphocytereceptor
famili
peripher
blood
intracytoplasm
inclus
bodi
identifi
ciliat
bronchial
epithelium
children
acut
kd
presenc
inclus
bodi
inflam
tissu
acut
ill
kd
suggest
infect
due
intracellular
pathogen
viru
autoimmun
mechan
kd
pathogenesi
also
propos
spontan
resolut
kd
gener
nonrecur
natur
make
theori
less
plausibl
kd
caus
vascul
sever
mediums
arteri
patholog
examin
reveal
small
arteriol
larger
arteri
capillari
vein
also
affect
lesser
extent
endotheli
cell
undergo
histolog
chang
consist
endotheli
cell
activ
endotheli
cell
damag
morpholog
featur
includ
enlarg
endotheli
cell
increas
synthet
organel
increas
replic
endotheli
cell
mark
increas
adhes
leukocyt
endotheli
wall
endotheli
cell
necrosi
extracellular
fibrin
deposit
level
varieti
inflammatori
cytokin
increas
serum
acut
kd
peripher
blood
mononuclear
cell
patient
spontan
secret
high
level
percentag
tnfposit
case
kd
patient
coronari
involv
higher
patient
without
coronari
involv
find
suggest
activ
monocytesmacrophag
activ
play
import
role
pathogenesi
kd
furthermor
presenc
circul
cytotox
antiendotheli
cell
antibodi
reactiv
cytokineinduc
activ
antigen
vascular
endothelium
report
leung
et
al
found
igg
igm
antibodi
acut
kd
sera
caus
lysi
endotheli
cell
stimul
tnf
thu
circul
cytotox
antiendotheli
cell
antibodi
reactiv
cytokineinduc
activ
antigen
vascular
endothelium
thank
observ
postul
least
two
requir
endotheli
injuri
kd
increas
cytokin
product
trigger
unknown
etiolog
agent
toxin
induc
new
endotheli
antigen
gener
cytotox
antibodi
direct
induc
endotheli
antigen
possibl
relat
polyclon
bcell
activ
diseas
infiltr
macrophag
lymphocyt
cellular
compon
arteri
wall
myofibroblast
import
diseas
pathogenesi
secret
number
inflammatori
mediat
enzym
molecul
vascular
endotheli
growth
factor
vegf
contribut
vascular
leakag
edema
patholog
studi
demonstr
transient
infiltr
neutrophil
earli
stage
acut
kd
infiltr
mononuclear
cell
recent
observ
suggest
nitric
oxid
produc
neutrophil
role
trigger
earli
endotheli
dysfunct
kd
neutrophil
acut
kd
gener
reactiv
oxygen
speci
ro
consider
product
exclus
earli
stage
kd
kobayashi
et
al
demonstr
acut
phase
kd
express
adhes
molecul
significantli
increas
polymorphonuclear
leucocyt
pmn
gener
promot
firm
attach
pmn
endothelium
allow
transendotheli
migrat
inflam
tissu
addit
pmn
gener
larg
amount
ro
therefor
enhanc
express
induc
circul
inflammatori
cytokin
like
promot
adhes
transendotheli
migrat
leucocyt
kd
sever
clinic
studi
report
activ
pmn
may
contribut
sever
kd
addit
oligoclon
iga
plasmacel
infiltr
also
demonstr
arteri
wall
upper
respiratori
tract
pancrea
patient
acut
kd
presenc
igaproduc
cell
within
vascular
wall
may
indic
antigendriven
immun
respons
etiolog
agent
respiratori
gastrointestin
portal
entri
thymic
deriv
natur
regulatori
cell
treg
suppress
wide
varieti
effector
immun
cell
sever
diseas
document
secondari
loss
treg
popul
mice
human
furuno
et
al
character
involv
treg
kd
patient
acut
phase
kd
exhibit
significantli
lower
frequenc
treg
peripher
blood
mononuclear
cell
pbmc
compar
healthi
control
immunolog
featur
peripher
blood
acut
kd
summar
tabl
thu
kd
character
mark
immun
activ
associ
cytotox
antiendotheli
cell
antibodi
increas
cytokin
product
could
contribut
endotheli
cell
damag
observ
diseas
random
control
trial
shown
singl
infus
gkg
ivig
given
day
onset
fever
elimin
fever
children
within
h
significantli
reduc
risk
coronari
arteri
aneurysm
two
metaanalys
demonstr
doserespons
effect
higher
dose
given
singl
infus
greatest
efficaci
therapi
institut
within
first
day
possibl
within
day
ill
clinic
studi
compar
efficaci
ivig
product
fail
find
signific
differ
commerci
prepar
ivig
even
treat
highdos
ivig
within
first
day
ill
children
kd
develop
least
transient
coronari
arteri
dilat
develop
giant
aneurysm
aspirin
remain
one
mainstay
therapi
antiinflammatori
antithrombot
action
acut
phase
ill
aspirin
administ
antiinflammatori
dose
mgkg
per
day
dose
ivig
highdos
aspirin
ivig
appear
possess
addit
antiinflammatori
effect
practic
regard
durat
highdos
aspirin
administr
vari
across
institut
highdos
aspirin
discontinu
clinician
begin
lowdos
aspirin
mgkg
per
day
given
singl
dose
tabl
immunolog
featur
peripher
blood
acut
kd
circul
antibodi
activ
endotheli
cell
antigen
increas
cytokin
product
lowdos
aspirin
antiplatelet
effect
continu
six
eight
week
diseas
onset
coronari
arteri
abnorm
indefinit
abnorm
present
approxim
patient
kd
fail
defervesc
initi
ivig
therapi
failur
respond
usual
defin
persist
recrudesc
fever
h
complet
initi
ivig
infus
abe
et
al
report
polycythemia
rubra
vera
granulocyt
colonystimul
factor
level
may
good
biomark
predict
respons
ivig
patient
kd
egami
et
al
gener
predict
score
resist
ivig
assign
point
infant
younger
month
day
ill
platelet
count
l
crp
mgdl
point
assign
alanin
aminotransferas
iul
use
cutoff
point
predict
score
could
identifi
ivigresist
group
sensit
specif
ogata
et
al
investig
transcript
abund
leukocyt
ivigrespons
patient
group
ivigresist
patient
group
b
use
microarray
analysi
treatment
ivigrespons
group
ivigresist
patient
group
b
predict
start
initi
treatment
use
egami
score
system
randomli
alloc
singleivig
treatment
group
group
ivigplusmethylprednisolon
ivmp
combin
therapi
group
group
transcript
relat
ivig
resist
develop
coronari
arteri
lesion
oncostatin
suppressor
cytokin
protein
carcinoembryon
antigenrel
cell
adhes
matrix
polycythemia
rubra
abund
group
b
patient
comparison
group
patient
risk
coronari
arteri
aneurysm
increas
refractori
kd
patient
control
clinic
trial
establish
optim
manag
control
data
lack
rel
role
repeat
dose
ivig
corticosteroid
antagonist
abciximab
cytotox
agent
methotrex
cyclophosphamid
cyclosporin
plasma
exchang
patient
refractori
kd
remain
uncertain
american
heart
associ
guidelin
recommend
dose
ivig
gkg
children
remain
febril
h
first
dose
immunoglobulin
studi
shown
corticosteroid
reduc
fever
effect
steroid
coronari
arteri
abnorm
still
uncertain
recommend
steroid
treatment
restrict
children
infus
ivig
effect
allevi
fever
acut
inflamm
recent
furukawa
et
al
suggest
corticosteroid
may
use
compar
efficaci
second
dose
ivig
children
fail
respond
first
dose
commonli
use
steroid
regimen
intraven
puls
methyl
prednisolon
mgkg
h
administ
daili
day
one
retrospect
studi
children
ivigresist
kd
infliximab
human
monoclon
antibodi
use
success
dose
mgkg
abrupt
defervesc
febril
patient
infus
reaction
twelv
patient
coronari
abnorm
infliximab
therapi
four
transient
dilat
resolv
postinfliximab
infus
three
aneurysm
five
ectasia
phase
clinic
trial
includ
subject
receiv
infliximab
demonstr
treatment
safe
well
toler
patient
resist
ivig
abciximab
monoclon
platelet
glycoprotein
iibiiia
receptor
inhibitor
use
treat
patient
acut
subacut
phase
kd
larg
coronari
aneurysm
patient
receiv
abciximab
plu
standard
therapi
compar
histor
control
treat
standard
therapi
alon
show
greater
regress
maximum
aneurysm
diamet
suggest
treatment
abciximab
might
promot
vascular
remodel
prospect
control
trial
need
methotrex
seventeen
patient
kd
persist
fever
recrudesc
fever
treatment
ivig
given
methotrex
lowdos
oral
methotrex
treatment
result
quick
resolut
fever
rapid
improv
inflamm
marker
without
caus
advers
effect
plasma
exchang
report
uncontrol
clinic
trial
effect
therapi
patient
refractori
ivig
lower
incid
coronari
arteri
aneurysm
risk
plasma
exchang
gener
recommend
therapi
use
small
number
patient
data
limit
offici
recommend
acut
manag
patient
coronari
arteri
abnorm
depend
extent
sever
lesion
although
lowdos
aspirin
adequ
patient
mild
diseas
dilat
small
stabl
aneurysm
addit
therapi
antiplatelet
agent
heparin
may
requir
patient
sever
diseas
increas
risk
thrombosi
abnorm
blood
flow
coronari
aneurysm
patient
larg
giant
coronari
arteri
aneurysm
intern
diamet
greater
mm
maintain
aspirin
clopidogrel
warfarin
prevent
thrombosi
within
aneurysm
myocardi
infarct
ivig
polyspecif
immunoglobulin
igg
prepar
purifi
plasma
pool
sever
thousand
healthi
donor
ivig
safe
prepar
long
term
side
effect
ivig
initi
use
substitut
treatment
patient
immunodefici
subsequ
use
treatment
wide
rang
autoimmun
system
inflammatori
diseas
kd
ivig
first
report
furusho
et
al
effect
reduc
incid
coronari
arteri
lesion
although
treatment
ivig
effect
therapi
kd
precis
mechan
action
fulli
understood
clinic
ivig
reduc
preval
coronari
arteri
abnorm
reduc
tissu
inflamm
immun
activ
potenti
mechan
action
ivig
summar
fig
tabl
shown
ivig
inhibit
endotheli
cell
prolifer
doseand
timedepend
manner
ivig
also
downregul
express
mrna
encod
major
adhes
molecul
chemokin
mcsf
gmcsf
proinflammatori
cytokin
significantli
implic
leukocyt
recruit
observ
kd
endothelium
play
central
role
immunopatholog
kd
like
ivig
exert
benefici
effect
modul
endotheli
cell
function
integrin
major
group
adhes
molecul
serv
adher
signal
function
integrin
play
critic
role
cell
differenti
embryogen
develop
inflamm
immun
respons
mani
integrin
share
affin
toward
rgd
recognit
sequenc
argglyasp
motif
extracellular
matrix
ligand
abl
discrimin
differ
rgdcontain
protein
shown
ivig
contain
antibodi
bind
human
rgdcontain
integrin
ligand
biolog
relev
antirgd
antibodi
ivig
demonstr
abil
inhibit
blymphocyt
adhes
fibronectin
presenc
natur
igg
antibodi
rgd
motif
may
contribut
immunomodulatori
antiinflammatori
effect
ivig
kd
ivig
contain
antiidiotyp
antibodi
directli
inhibit
bind
sever
diseaseassoci
autoantibodi
target
instanc
ivig
shown
contain
antiidiotyp
antibodi
neutral
antifactor
viii
antibodi
patient
hemophilia
anca
vascul
antiacetylcholin
receptor
autoantibodi
patient
myastheneia
gravi
nevertheless
leung
et
al
demonstr
ivig
reduc
cytotox
antibodi
endotheli
cell
six
patient
test
furthermor
studi
blood
skin
biopsi
obtain
acut
ks
patient
prior
treatment
ivig
indic
ivig
treatment
reduc
serum
cytotox
antiendotheli
cell
antibodi
activ
nerv
growth
factor
ngf
neurotrophin
regul
develop
surviv
function
neuron
nonneuron
cell
may
play
role
mani
inflammatori
diseas
due
abil
stimul
releas
inflammatori
neuropeptid
acut
phase
kd
serum
level
ngf
elev
studi
warrington
et
al
show
antingf
antibodi
present
ivig
author
suggest
therapeut
effect
ivig
may
lie
antingf
compon
ivig
tabl
propos
mechan
action
ivig
kawasaki
diseas
antiidiotyp
inhibit
antiendotheli
antibodi
antingf
effect
reduct
inflammatori
cytokin
product
inhibit
cytokineinduc
endotheli
cell
activ
fc
receptor
blockad
suppress
antibodi
synthesi
reduct
product
neutrophil
augment
tcell
suppressor
activ
neutral
bacteri
superantigen
etiolog
agent
reduct
inflammatori
cytokin
product
ivig
modul
product
cytokin
exert
antiinflammatori
effect
respons
patient
serum
level
proinflammatori
cytokin
decreas
ivig
therapi
find
indic
effect
ivig
kd
mediat
mainli
robust
suppress
activ
immun
cell
peripher
circul
may
play
role
acut
system
inflammatori
respons
kd
major
symptom
diseas
attenu
decreas
ivig
therapi
use
murin
model
kd
lau
et
al
recent
shown
ivig
inhibit
lymphocyt
activ
product
also
shown
ivig
effect
matrix
metalloproteinas
activ
murin
model
kd
activ
critic
role
develop
coronari
arteri
elastin
breakdown
ichiyama
et
al
demonstr
ivig
inhibit
activ
monocytesmacrophag
transcript
factor
gene
encod
proinflammatori
cytokin
chemokin
adhes
molecul
mediat
inflamm
examin
gene
express
profil
pbmc
purifi
monocyt
patient
acut
kd
ivig
therapi
abe
et
al
infer
ivig
suppress
array
immun
activ
gene
monocyt
includ
activ
heterocomplex
complex
shown
enhanc
monocyt
adhes
endotheli
cell
caus
neutrophil
chemotaxi
express
monocyt
reduc
follow
ivig
therapi
interestingli
demonstr
ivig
therapi
patient
kd
increas
express
inhibitori
fc
receptor
peripher
blood
monocytesmacrophag
acut
stage
takatsuki
et
al
evalu
oxid
stress
acut
phase
kd
measur
urinari
inde
measur
urinari
excret
shown
reflect
enhanc
oxid
stress
demonstr
ivig
reduc
vascular
oxid
stress
patient
kd
amount
produc
neutrophil
decreas
ivig
treatment
signific
chang
ro
product
import
role
trigger
earli
endotheli
dysfunct
kd
leung
et
al
shown
ivig
treatment
kd
caus
signific
reduct
number
antibodyproduc
b
cell
author
report
ivig
lead
signific
increas
circul
suppressor
cell
signific
reduct
activ
helper
cell
kd
import
caus
fever
young
children
common
caus
acquir
heart
diseas
character
immun
activ
increas
cytokin
product
recent
observ
allow
better
understand
pathogen
event
kd
could
infecti
diseas
genet
predispos
individu
determin
caus
agent
could
improv
diagnosi
therapi
prevent
kd
ivig
reduc
preval
coronari
arteri
abnorm
reduc
immun
activ
clarif
mechan
action
ivig
kd
provid
insight
pathogenesi
andor
etiolog
help
conceiv
target
therapeut
strategi
disord
kawasaki
diseas
pediatr
vascul
associ
develop
coronari
arteri
abnorm
untreat
patient
epidemiolog
immunolog
featur
suggest
role
pathogenesi
kd
intracellular
pathogen
viru
genet
suscept
host
endotheli
injuri
kd
due
increas
cytokin
product
gener
cytotox
antibodi
endotheli
cell
ivig
mainstay
treatment
kd
markedli
reduc
incid
coronari
arteri
abnorm
ten
percent
patient
kd
fail
defervesc
initi
ivig
therapi
mode
action
ivig
kd
fulli
understood
although
sever
mutual
nonexclus
mechan
propos
involv
effect
endotheli
cell
macrophag
monocyt
neutrophil
b
cell
express
adhes
molecul
cytokin
product
tolerogen
peptid
amelior
murin
lupu
via
upregul
function
regulatori
cell
immunomodul
cytokin
product
present
studi
sthoeger
zm
et
al
hum
immunol
analyz
abil
similarli
affect
gene
express
regulatori
cell
incub
peripher
blood
mononuclear
cell
pbmc
lupu
patient
end
peripher
blood
mononuclear
cell
pbmc
lupu
patient
five
genderand
agematch
healthi
control
cultur
control
peptid
gene
express
regulatori
tcell
assess
significantli
downregul
interleukin
beta
interferon
ifngamma
gene
express
furthermor
upregul
express
antiapoptot
bclxl
molecul
downregul
proapoptot
result
reduc
rate
apoptosi
increas
express
transform
growth
factor
tgf
betta
neg
regul
signific
effect
observ
use
control
peptid
pbmc
healthi
donor
incub
elev
gene
express
due
hcdrinduc
upregul
tgfbetta
result
increas
function
regulatori
cell
abil
regulatori
cell
diminish
ifngamma
express
upregulatetgfbeta
abrog
addit
neutral
antibodi
confirm
role
benefici
effect
tolerogen
peptid
downregul
pathogen
cytokin
apoptosi
upregul
immunosuppress
molecul
regulatori
cell
peripher
blood
mononuclear
cell
lupu
patient
irrespect
phenotyp
use
defin
signific
decreas
treg
cell
proport
patient
granulomat
diseas
immun
cytopenia
allow
definit
subgroup
cvid
patient
abnorm
low
treg
cell
higher
rate
two
manifest
well
autoimmun
diseas
gener
also
signific
reduct
proport
treg
cell
freiburg
group
compar
cvid
patient
control
differ
pari
group
reduct
treg
cell
subset
cvid
patient
may
relev
clinic
manifest
may
contribut
understand
pathogenesi
cvid
complic
